# Eutilex Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eutilex-co

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.eutilex.com
- Total disclosed funding: $1.8M
- Latest round: Series A (Dec 9, 2016)
- Investors on record: 4

## About

Eutilex Co., Ltd. is a South Korean biotechnology company focused on developing advanced immunotherapeutics, particularly in the areas of antibody therapies and CAR-T cell therapies, aimed at treating challenging diseases and improving patient outcomes.Founded in 2015, Eutilex Co., Ltd. specializes in immunotherapy solutions. The company is headquartered in Seoul, South Korea. In May 2021, Eutilex raised KRW 22.5 billion in PIPE funding, with major investments from Focus Asset Management and Susung Asset Management, totaling KRW 22.5 billion raised to date, establishing itself as a prominent player in the biopharmaceutical industry.Eutilex specializes in the development of breakthrough immunotherapeutics, focusing primarily on antibody therapies and T cell therapies, including CAR-T cell therapies. These innovative treatment solutions aim to address various types of incurable diseases, particularly those that are resistant to traditional therapies. Eutilex's products are designed to enhance therapeutic efficacy against conditions with limited treatment options, targeting healthcare providers like hospitals and specialized clinics across Asia, Europe, and North America.In 2024, Eutilex reported a revenue of KRW 6,989,460.7 and an EBITDA of -KRW 17,835,020.9. The company generates revenue through partnerships and collaborations with healthcare institutions and pharmaceutical companies, primarily supplying its therapies directly to hospitals and treatment centers, ensuring alignment with industry standards.Eutilex plans to leverage its recent funding of KRW 22.5 billion raised in May 2021 to accelerate the development of new immunotherapy products, with anticipated launches in the next 1-2 years. The company aims to expand into European and North American markets by 2025, positioning itself to meet the growing demand for advanced cancer treatment options. This funding will support the launch of new therapies and facilitate entry into these targeted regions.

## Funding rounds

- Series A, Dec 9, 2016, $1.8M — G.N.TECH Venture Capital, Kolon Investment, DS Asset Investment, SNU Bio Angel

## Investors

- G.N.TECH Venture Capital (https://capitalatlas.ai/funds/g-n-tech-venture-capital) — Series A
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A
- DS Asset Investment — Series A
- SNU Bio Angel — Series A